PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors.

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

A new PanCAN-authored paper uses feedback provided by patients with pancreatic cancer to identify trends in reporting pain.

Estadificación - Pancreatic Cancer Action NetworkCategoría de resección quirúrgica Extirpable Posiblemente extirpable No extirpable Extirpable Esta categoría se utiliza para tumores que se pueden ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit outlines the latest advances in pancreatic cancer and offers key insights from ASCO GI 2025.

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Calif. – (January 16, 2025) – After ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and treating pancreatic cancer in 2024.

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...

In a Phase III clinical trial, a therapy known as Tumor Treating Fields (TTFields) increased survival for patients whose pancreatic cancer had not spread to other organs but cannot be removed by ...